Navigation Links
Obesity Care Continuum (OCC) Applauds FDA for Approval of New Obesity Drug
Date:6/27/2012

WASHINGTON, June 27, 2012 /PRNewswire-USNewswire/ -- Today, members of the Obesity Care Continuum (OCC) applauded the Food and Drug Administration's (FDA) approval of a new obesity drug – Belviq (lorcaserin HCl). Belviq is the first obesity drug to be approved in the past 13 years.

"This is a tremendous step forward in addressing our most pressing health problem. Healthcare professionals now have a new option to help their patients affected by obesity manage this chronic condition. We are happy to see this latest evidence that the FDA is joining the effort to treat obesity seriously," said Dr. Patrick O'Neil, President of The Obesity Society.

Dr. O'Neil continued, "At the same time, it is important to understand that this medication will not work overnight or by itself. Lifestyle changes and support from qualified professionals are still necessary. This is an obesity medication, not a diet pill."

The OCC supports the FDA's continued dedication to excellence in ensuring the safety and effectiveness of new obesity treatments. With more than 93 million Americans affected by obesity, it is imperative to continue this proactive momentum and forward-thinking approach with all safe and effective therapies for the disease.

"We are very pleased with the FDA's decision. These are serious medications for a serious issue. In order for us to fight this epidemic, the right patients must receive the right treatment from a qualified physician in combination with a diet and exercise program," said Joe Nadglowski, Obesity Action Coalition (OAC) President and CEO.

About the Obesity Care Continuum (OCC):

With a combined membership of more than 125,000 healthcare professionals and patient advocates, the Obesity Care Continuum (OCC) is dedicated to promoting access to, and coverage of, the continuum of care surrounding the treatment of overweight and obesity. The OCC also challenges weight bias and stigma oriented policies – whenever and wherever they occur. The OCC is a coalition of the Obesity Action Coalition (OAC), the Obesity Society (TOS), and the American Society for Metabolic and Bariatric Surgery (ASMBS).


'/>"/>
SOURCE Obesity Care Continuum
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Obesity journal publishes new study on lorcaserin, a weight-loss medication recommended for approval by FDA advisory panel
2. LTCLINK-Tank Competition Announced To Introduce Your Emerging Product to the Aging Care Continuum
3. Omega Laboratories Applauds the Adoption of Enzyme Immunoassay (EIA) by Major Hair Testing Laboratories
4. CHPA Applauds Arizonas Adoption Of HB 2263
5. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
6. CHPA Applauds Alabamas Adoption Of HB 363
7. CHPA Applauds Alabama Senates Passage of Anti-Meth Bill
8. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
9. China Biologic Receives SFDA Manufacturing Approval Certificate for Human Coagulation Factor VIII
10. ERT Announces Stockholder Approval of Merger
11. CMC Biologics Achieves Successful Pre-Approval European GMP Inspection by MHRA for Commercial Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
Breaking Medicine News(10 mins):